Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
2 other identifiers
interventional
46
1 country
4
Brief Summary
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Nov 2021
Typical duration for phase_2
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 19, 2021
CompletedFirst Posted
Study publicly available on registry
April 22, 2021
CompletedStudy Start
First participant enrolled
November 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 11, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 11, 2025
CompletedFebruary 4, 2026
February 1, 2026
3.6 years
April 19, 2021
February 2, 2026
Conditions
Outcome Measures
Primary Outcomes (5)
Thoracic cavity volume measured in liters.
4 years
RBC/barrier signal ratio (unitless).
4 years
Coefficient of repeatability of RBC/barrier signal ratio (unitless).
4 years
Echo time to separate RBC and barrier signals by 90 degrees (ms).
4 years
Population-wide RBC/barrier signal ratio (unitless).
4 years
Study Arms (2)
Patients with Interstitial Lung Disease
ACTIVE COMPARATORHealthy Volunteers
ACTIVE COMPARATORInterventions
Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
Eligibility Criteria
You may not qualify if:
- Outpatients of either gender, age greater than or equal to 18 years
- Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
- Subject has no diagnosed pulmonary conditions
- Subject has not smoked in the previous 5 years
- Smoking history, if any, is less than or equal to 5 pack-years
- No history of using other inhaled products more than 1 time per week for \> 1 year
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Resting oxygen saturation on room air \<90%
- Respiratory illness of a bacterial or viral etiology within 30 days of MRI
- Subject has history of any known ventricular cardiac arrhythmia
- Subject has history of cardiac arrest within the last year
- Subject does not fit into Xe vest coil used for MRI 129
- Subject cannot hold his/her breath for 15 seconds
- +16 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bastiaan Driehuyslead
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
- Children's Hospital Medical Center, Cincinnaticollaborator
- University of Cincinnaticollaborator
- University of Iowacollaborator
Study Sites (4)
University of Iowa
Iowa City, Iowa, 52242, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
University of Cincinnati
Cincinnati, Ohio, 45219, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joseph Mammarappallil, MD
Duke University
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Radiology
Study Record Dates
First Submitted
April 19, 2021
First Posted
April 22, 2021
Study Start
November 12, 2021
Primary Completion
June 11, 2025
Study Completion
June 11, 2025
Last Updated
February 4, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI. In all instances we will adhere to the NIH Sharing Policies and Related Guidance on NIH-Funded Research Resources for Recipients of NIH Grants and Contracts on Obtaining (https://grants.nih.gov/policy/sharing.htm) and Disseminating Biomedical Research Re-sources (issued December 1999). However, we intend to greatly exceed these requirements, making as much of our work freely available to the broader research community either before, or immediately after publication of manuscripts, as well as through PubMedCentral. While we we will provide relevant protocols upon request at any time, we further intend to pursue several proactive data sharing mechanisms.
- Access Criteria
- We are committed to making de-identified datasets and image analysis available to to qualified investigators. When required scientifically, data including identifiers will be shared under an agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data appropriately; and (3) a commitment to destroying or returning the data after analyses are completed.
A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI.